Literature DB >> 1980827

A comparison of masking effects of haloperidol versus molindone in tardive dyskinesia.

W M Glazer1, H Hafez.   

Abstract

An experimental method was utilized to compare the masking effects of two neuroleptic agents--molindone and haloperidol--on 18 neuroleptic-treated schizophrenic patients exhibiting operationally defined withdrawal-exacerbated tardive dyskinesia. After a week on one of these two medications at preestablished doses equivalent to that of the pre-study neuroleptic, molindone-masked total AIMS scores by significantly less (12%) than haloperidol (27%). Similarly, during a second week when the dose of these neuroleptics was equivalent to 200% that of the pre-study dose, molindone masked the total AIMS score significantly less (23%) as compared to haloperidol (53%). Several interpretations of this finding are considered. This study demonstrates the feasibility of a method that may offer a model for understanding pharmacological differences among neuroleptic medications.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1980827     DOI: 10.1016/0920-9964(90)90016-z

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  5 in total

Review 1.  Antipsychotic medication for elderly people with schizophrenia.

Authors:  R G Marriott; W Neil; S Waddingham
Journal:  Cochrane Database Syst Rev       Date:  2006-01-25

2.  Haloperidol discontinuation for people with schizophrenia.

Authors:  Adib Essali; Khaled Turkmani; Shaimaa Aboudamaah; Alaa AbouDamaah; Mohammad Reyad Diaa Aldeen; Mohamad Essam Marwa; Nawar AlMounayer
Journal:  Cochrane Database Syst Rev       Date:  2019-04-21

3.  Neuroleptic-induced vacuous chewing movements in rodents: incidence and effects of long-term increases in haloperidol dose.

Authors:  M F Egan; T M Hyde; J E Kleinman; R J Wyatt
Journal:  Psychopharmacology (Berl)       Date:  1995-01       Impact factor: 4.530

Review 4.  Antipsychotic reduction and/or cessation and antipsychotics as specific treatments for tardive dyskinesia.

Authors:  Hanna Bergman; John Rathbone; Vivek Agarwal; Karla Soares-Weiser
Journal:  Cochrane Database Syst Rev       Date:  2018-02-06

5.  Mimicking of Phase I Metabolism Reactions of Molindone by HLM and Photocatalytic Methods with the Use of UHPLC-MS/MS.

Authors:  Maciej Gawlik; Vladimir Savic; Milos Jovanovic; Robert Skibiński
Journal:  Molecules       Date:  2020-03-17       Impact factor: 4.411

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.